## Supporting Information

# Alchemical Approach Performance in Calculating 

## the Ligand-Binding Free Energy

Son Tung Ngo, ${ }^{\text {ab* }}$ Quynh Mai Thai, ${ }^{\text {ab }}$ Trung Hai Nguyen, ${ }^{\text {ab }}$ Nguyen Ngoc Tuan, ${ }^{\mathrm{c}}$ T. Ngoc Han Pham, ${ }^{\text {d }}$ Huong T. T. Phung, ${ }^{\text {d }}$ and Duong Tuan Quang ${ }^{\text {e* }}$<br>${ }^{a}$ Laboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City, Vietnam<br>${ }^{b}$ Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, Vietnam<br>${ }^{c}$ Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam<br>${ }^{d}$ NTT Hi-Tech Institute, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam<br>${ }^{e}$ Department of Chemistry, Hue University, Thua Thien Hue Province, Hue City, Vietnam<br>*Email: ngosontung@tdtu.edu.vn and dtquang@hueuni.edu.vn

Sequence comparison between Homo sapiens and Rattus norvegicus of Glutamate Receptor, Ionotropic Kainate 1 Pairwise Alignment
Sequence 1: 2ZNS (Homo sapiens)
Sequence 2: 4DLD (Rattus norvegicus)
Sequence ends allowed to slide over each other
Alignment score: 248

Identities: 0.9766537
Similarities: 0.9766537
Similarity Matrix: MATCH

2ZNS EANRTLIVTTILEEPYVMYRKSDKPLYGNDRFEGYCLDLLKELSNILGFIYDVKLVPDGKYGAQNDKGEWNGMVKELIDH 4DLD --NRTLIVTTILEEPYVMYRKSDKPLYGNDRFEGYCLDLLKELSNILGFLYDVKLVPDGKYGAQNDKGEWNGMVKELIDH

2ZNS RADLAVAPLTITYVREKVIDFSKPFMTLGISILYRKGTPIDSADDLAKQTKIEYGAVRDGSTMTFFKKSKISTYEKMWAF
4DLD RADLAVAPLTITYVREKVIDFSKPFMTLGISILYRKGTPIDSADDLAKQTKIEYGAVRDGSTMTFFKKSKISTYEKMWAF

2ZNS MSSRQQTALVRNSDEGIQRVLTTDYALLMESTSIEYVTQRNCNLTQIGGLIDSKGYGVGTPIGSPYRDKITIAILQLQEE 4DLD MSSRQQSALVKNSDEGIQRVLTTDYALLMESTSIEYVTQRNCNLTQIGGLIDSKGYGVGTPIGSPYRDKITIAILQLQEE

2ZNS GKLHMMKEKWWRGNGC-
4DLD GKLHMMKEKWWRGNGCP

Table S1. 2D and 3D structure for all ligands of AmpC, GluK1, Hsp90 and SARS-CoV-2 Mpro systems
N ${ }^{\mathbf{N}}$ PDB ID
2R9W
9
2RSO

(3FVK

| 21 | 2QG0 |  |  |
| :---: | :---: | :---: | :---: |
| 22 | 2QG2 |  |  |
| 23 | 3K97 |  |  |

27
29
31
34
37


Table S2. All-atom RMSD of AmpC + ligand and ligand in solution systems.

| N ${ }^{0}$ | PDB ID | Complex in Solution | Ligand in Solution |
| :---: | :---: | :---: | :---: |
| 1 | 1XGI |  |  |
| 2 | 1XGJ |  |  |
| 3 | 2HDU |  |  |


| 4 | 2PU2 |  |  |
| :---: | :---: | :---: | :---: |
| 5 | 2R9W |  |  |
| 6 | 2R9X |  |  |


| 7 | 3GR2 |  |  |
| :---: | :---: | :---: | :---: |
| 8 | 4KZ3 |  |  |
| 9 | 4K25 |  |  |


| 10 | 40KP |  |  |
| :---: | :---: | :---: | :---: |

Table S3. All-atom RMSD of GluK1 + ligand and ligand in solution systems.

| $\mathrm{N}^{0}$ | PDB ID | Complex in Solution | Ligand in Solution |
| :---: | :---: | :---: | :---: |
| 1 | 1VSO |  |  |
| 2 | 2PBW |  |  |
| 3 | 2ZNS |  |  |


| 4 | 2ZNU |  |  |
| :---: | :---: | :---: | :---: |
| 5 | 3FKV |  |  |
| 6 | 3FVN |  |  |
| 7 | 3FVG |  |  |


| 8 | 3VF1 |  |  |
| :---: | :---: | :---: | :---: |
| 9 | 4DLD |  |  |
| 10 | 4EOX |  |  |

Table S4. All-atom RMSD of Hsp90 + ligand and ligand in solution systems.

| $\mathrm{N}^{0}$ | PDB ID | Complex in Solution | Ligand in Solution |
| :---: | :---: | :---: | :---: |
| 1 | 2QG0 |  |  |
| 2 | 2QG2 |  |  |
| 3 | 3K97 |  |  |


| 4 | 3NMQ |  |  |
| :---: | :---: | :---: | :---: |
| 5 | 3QDD |  |  |
| 6 | 3R4M |  |  |


| 7 | 4CWF |  |  |
| :---: | :---: | :---: | :---: |
| 8 | 4CWT |  |  |
| 9 | 4NH8 |  |  |



Table S5. All-atom RMSD of SARS-CoV-2 Mpro + ligand and ligand in solution systems.


| 4 | 6XMK |  |  |
| :---: | :---: | :---: | :---: |
| 5 | 7B3E |  |  |
| 6 | 7181 |  |  |


| 7 | 7LDL |  |  |
| :---: | :---: | :---: | :---: |
| 8 | 7NG3 |  |  |
| 9 | 7CBT |  |  |




Figure S1. Thermodynamics diagram of FEP calculations. (A) full-interaction state of a ligand with surrounding protein and solvation; (B) full-interaction state of a ligand with surrounding solvation; (C) non-interaction state of a ligand with surrounding protein and solvation; (D) non-interaction state of a ligand with surrounding solvation.


Figure S2. SC and HB Contacts between AmpC Residues and Inhibitors. The values were computed over the interval 25-50 ns of MD simulations.


Figure S3. SC and HB Contacts between GluK1 Residues and Inhibitors. The values were computed over the interval 25-50 ns of MD simulations.


Figure S4. SC and HB Contacts between Hsp90 Residues and Inhibitors. The values were computed over the interval 25-50 ns of MD simulations.


Figure S5. SC and HB Contacts between SARS-CoV-2 Mpro Residues and Inhibitors. The values were computed over the interval 25-50 ns of MD simulations.

Table S6. Calculated versus Experimental Binding Affinities between AmpC, GluK1, Hsp90, SARS-CoV-2 Mpro and its inhibitors

| $\mathrm{N}^{0}$ | PDB ID | PDB ID | $\Delta \boldsymbol{G}_{\text {cou }}$ | $\Delta \boldsymbol{G}_{v d W}$ | $\Delta \boldsymbol{G}_{F E P}$ | $\Delta G_{E X P}{ }^{\text {b }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | AmpC | 1XGJ | -2.41 | -5.10 | $-7.50 \pm 1.74$ | -8.24 |
| 2 | GluK1 | 3FV1 | -21.90 | -0.78 | $-22.68 \pm 0.24$ | -12.77 |
| 3 | Hsp90 | 3 K 97 | $-2.74$ | -8.66 | $-11.40 \pm 0.91$ | -10.98 |
| 4 | SARS-CoV-2 Mpro | 6M2N | -0.67 | -5.83 | $-6.51 \pm 0.64$ | -8.25 |

The unit is $\mathrm{kcal}^{\mathrm{mol}}{ }^{-1}$.

Table S7. All-atom RMSD of AmpC, GluK1, Hsp90, SARS-CoV-2 Mpro + ligand and ligand in solution systems.

| $\mathrm{N}^{0}$ | PDB ID | Complex in Solution | Ligand in Solution |
| :---: | :---: | :---: | :---: |
| 1 | 1XGJ |  |  |
| 2 | 3FV1 |  |  |


| 3 | 3K97 |  |  |
| :---: | :---: | :---: | :---: |
| 4 | 6M2N |  |  |



Figure S6. Time dependence of binding free energies for solvated complexes: (A) AmpC (1XGJ), (B) GluK1 (3FV1), Hsp90 (3K97), SARS-CoV-2 Mpro ( $6 M 2 N$ ). The values collected in the equilibrium region were used to calculate $\Delta \mathrm{G}_{\text {fep. }}$. The error bars show the root mean square deviations.

